Skip to main content
All lobbying clients

BIOMARIN PHARMACEUTICAL INC.

Lobbying client · California · filed 2025 to 2026

$2,800,000 Reported spend
18 Filings counted
2 Outside firms hired
12 Bills named

Spend is reported income plus in-house expenses across 18 filings. 4 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 3 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as BIOMARIN PHARMACEUTICAL, INC.

 Who filed for this client 3

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 12
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    4 filings
  • H.R. 1509
    Accelerating Kids’ Access to Care Act of 2025
    4 filings
  • S. 1637
    MVP Act
    3 filings
  • S. 752
    Accelerating Kids’ Access to Care Act
    3 filings
  • S. 932
    Give Kids a Chance Act of 2025
    2 filings
  • H.R. 1
    One Big Beautiful Bill Act
    1 filing
  • H.R. 10359
    Priority for Pediatric Cures Act
    1 filing
  • H.R. 10571
    Surge to Save Newborns Act
    1 filing
  • H.R. 1414
    Cameron’s Law
    1 filing
  • H.R. 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and E…
    1 filing
  • H.R. 946
    ORPHAN Cures Act
    1 filing
  • S. 1862
    ORPHAN Cures Act
    1 filing
 Reported by year 2 years
  • 2026 $1,220,000 6 filings
  • 2025 $1,580,000 12 filings
 Issues lobbied 8

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 9
  • HOUSE OF REPRESENTATIVES 16
  • SENATE 16
  • Health & Human Services, Dept of (HHS) 11
  • Food & Drug Administration (FDA) 6
  • Commerce, Dept of (DOC) 4
  • White House Office 4
  • Executive Office of the President (EOP) 3
  • Centers For Medicare and Medicaid Services (CMS) 1
  • Health Resources & Services Administration (HRSA) 1
 Recent filings 22 total
Q3 report
BIOMARIN PHARMACEUTICAL INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $200,000 expenses · posted Oct 20, 2026
View →
Q3 report
BGR GOVERNMENT AFFAIRS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q2 amendment
BIOMARIN PHARMACEUTICAL INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $340,000 expenses · posted Jul 20, 2026
View →
Q2 amendment
BIOMARIN PHARMACEUTICAL INC. Amended
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $340,000 expenses · posted Jul 20, 2026
View →
Q2 report
BIOMARIN PHARMACEUTICAL INC. Amended
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $340,000 expenses · posted Jul 20, 2026
View →
Q2 report
BGR GOVERNMENT AFFAIRS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q1 report
BIOMARIN PHARMACEUTICAL INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $530,000 expenses · posted Apr 20, 2026
View →
Q1 report
BGR GOVERNMENT AFFAIRS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q4 termination
LMH STRATEGIC SOLUTIONS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Apr 17, 2026
View →
Q4 report
BIOMARIN PHARMACEUTICAL INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $390,000 expenses · posted Jan 20, 2026
View →
Q4 report
BGR GOVERNMENT AFFAIRS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
LMH STRATEGIC SOLUTIONS Amended
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 12, 2026
View →
Q3 report
BIOMARIN PHARMACEUTICAL INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $270,000 expenses · posted Oct 20, 2025
View →
Q3 report
BGR GOVERNMENT AFFAIRS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025
View →
Q3 report
LMH STRATEGIC SOLUTIONS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 20, 2025
View →
Q2 amendment
LMH STRATEGIC SOLUTIONS
2nd Quarter 2025 (Apr 1 - June 30) · posted Oct 6, 2025
View →
Q2 report
LMH STRATEGIC SOLUTIONS Amended
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $10,000 income · posted Jul 21, 2025
View →
Q2 report
BIOMARIN PHARMACEUTICAL INC.
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $270,000 expenses · posted Jul 21, 2025
View →
Q2 report
BGR GOVERNMENT AFFAIRS
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 21, 2025
View →
Registration
LMH STRATEGIC SOLUTIONS
2nd Quarter 2025 (Apr 1 - June 30) · posted Jul 15, 2025
View →

Showing the 20 most recent of 22 filings. Search the explorer for "BIOMARIN PHARMACEUTICAL INC.".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem